[go: up one dir, main page]

AR063012A1 - Forma de dosificacion de liberacion controlada que contiene lercadinipina y un acido que mejora el funcionamiento - Google Patents

Forma de dosificacion de liberacion controlada que contiene lercadinipina y un acido que mejora el funcionamiento

Info

Publication number
AR063012A1
AR063012A1 ARP070104261A ARP070104261A AR063012A1 AR 063012 A1 AR063012 A1 AR 063012A1 AR P070104261 A ARP070104261 A AR P070104261A AR P070104261 A ARP070104261 A AR P070104261A AR 063012 A1 AR063012 A1 AR 063012A1
Authority
AR
Argentina
Prior art keywords
lercanidipine
dosage form
acid
controlled release
lercadinipine
Prior art date
Application number
ARP070104261A
Other languages
English (en)
Inventor
Pablo F A Carraud
Marcelo A Ricci
Mark G Meyer
Esteban Abel Abalo
Original Assignee
Osmotica Pharmaceutical Argent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osmotica Pharmaceutical Argent filed Critical Osmotica Pharmaceutical Argent
Publication of AR063012A1 publication Critical patent/AR063012A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Una forma de dosificacion de liberacion controlada que contiene lercanidipina, o una sal de la misma, un ácido que mejora el funcionamiento, y al menos algun otro excipiente farmacéutico exhibe un aumento de la disolucion in vitro de lercanidipina, un aumento de la estabilidad de almacenamiento basada en la degradacion reducida de lercanidipina, y/o un aumento de la biodisponibilidad in vivo de lercanidipina al compararla con otra forma de dosificacion de liberacion controlada similar que excluye el ácido que mejora el funcionamiento pero que contiene la misma cantidad de lercanidipina.
ARP070104261A 2006-09-28 2007-09-26 Forma de dosificacion de liberacion controlada que contiene lercadinipina y un acido que mejora el funcionamiento AR063012A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82736006P 2006-09-28 2006-09-28

Publications (1)

Publication Number Publication Date
AR063012A1 true AR063012A1 (es) 2008-12-23

Family

ID=39230557

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104261A AR063012A1 (es) 2006-09-28 2007-09-26 Forma de dosificacion de liberacion controlada que contiene lercadinipina y un acido que mejora el funcionamiento

Country Status (3)

Country Link
US (1) US20080175872A1 (es)
AR (1) AR063012A1 (es)
WO (1) WO2008037224A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102600146B (zh) * 2012-04-11 2014-10-08 兆科药业（合肥）有限公司 一种盐酸乐卡地平和氯沙坦钾复方制剂及其制备方法
TR201907094A2 (tr) * 2019-05-10 2020-11-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Lerkani̇di̇pi̇n ve enalapri̇l i̇çeren tablet formülasyonu

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8403866D0 (en) * 1984-02-14 1984-03-21 Recordati Chem Pharm Diphenylalkylaminoalkyl esters
US5696139A (en) * 1995-05-12 1997-12-09 Recordati S.A., Chemical And Pharmaceutical Company Use of S-enantiomers of 1,4-dihydropyridine derivatives for treating heart failure
US5767136A (en) * 1995-05-12 1998-06-16 Recordati, S.A. Chemical And Pharmaceutical Company 1,4-Dihydropyridines useful for prevention or reduction of atherosclerotic lesions on arterial walls
US6852737B2 (en) * 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
US20030069285A1 (en) * 2001-08-06 2003-04-10 Recordati Ireland Limited Novel solvate and crystalline forms of lercanidipine hydrochloride
JP4328832B2 (ja) * 2002-07-15 2009-09-09 サイバーレーザー株式会社 光再生増幅器
AR043395A1 (es) * 2003-02-28 2005-07-27 Recordati Ireland Ltd Terapia de combinacion para la hipertension utilizando lercanidipina y un bloqueante de los receptores de angiotensina ii
US7124972B2 (en) * 2003-09-04 2006-10-24 Scheer Bay Limited Partnership System and apparatus for manufacturing thermoplastic micropellets
WO2005053689A2 (en) * 2003-12-01 2005-06-16 Lifecycle Pharma A/S Pharmaceutical compositions comprising lercanidipine
DE10358132B3 (de) * 2003-12-12 2005-09-08 Ideal-Standard Gmbh & Co. Ohg Sanitärarmatur mit Einlochbefestigung
US7185676B2 (en) * 2004-08-17 2007-03-06 Ching Yu Huang Valve structure for faucets
TW200613275A (en) * 2004-08-24 2006-05-01 Recordati Ireland Ltd Lercanidipine salts
US20060165789A1 (en) * 2004-09-09 2006-07-27 Forest Laboratories, Inc. Lercanidipine modified release compositions
US20060165788A1 (en) * 2004-09-09 2006-07-27 Wattanaporn Abramowitz Lercanidipine pH dependent pulsatile release compositions
TW200616681A (en) * 2004-10-05 2006-06-01 Recordati Ireland Ltd Lercanidipine capsules
US20060280795A1 (en) * 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
TWI388345B (zh) * 2005-06-27 2013-03-11 Sankyo Co 用於高血壓之預防或治療之包含血管緊張素ⅱ受體拮抗劑及鈣通道阻斷劑之固體劑型

Also Published As

Publication number Publication date
WO2008037224A2 (es) 2008-04-03
WO2008037224A3 (es) 2008-09-12
US20080175872A1 (en) 2008-07-24

Similar Documents

Publication Publication Date Title
CR20110110A (es) Composicion farmaceutica
CO6280466A2 (es) Forma de dosificacion farmaceutica de liberacion controlada
UY33025A (es) Composicion farmaceutica que comprende un agonista de glp-1 metionina
DOP2012000133A (es) Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina
CL2011000798A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
MX2012003551A (es) Tabletas transformables via oral.
AR054060A1 (es) Forma de dosificacion farmaceutica unitaria
CL2011002968A1 (es) Forma de dosificacion de extrusion por fusion caliente de un ingrediente activo (a) incluido en una matriz que comprende un polimero (c), que el nucleo presenta una orientacion morfologica ortogonal respecto a la direccion longitudinal de extension de la forma de dosificacion; y su procedimiento de preparacion.
AR088382A1 (es) Formulaciones de etanercept estabilizadas con xilitol
JO3757B1 (ar) التركيبات الصيدلانية التي تشمل على نيلوتينيب أو أملاحه
CO6400186A2 (es) Tabletas de acetato de ulipristal
UY32764A (es) Preparaciones insulinicas que comprenden metionina
CO6311067A2 (es) Preparación de comprimido con liberación retardada que contiene polivinilpirrolidonas y principio activo
WO2009066146A3 (en) Stable solutions of sparingly soluble actives
MA31218B1 (fr) Forme galenique secable permettant une liberation modifiee du principe actif
CL2011000806A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
CL2007001752A1 (es) Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral.
ECSP11011001A (es) Composición farmacéutica sólida
ES2555778T3 (es) Mejora de la biodisponibilidad de principios activos con función amidina en medicamentos
UY32299A (es) Composiciones farmacéuticas líquidas
AR063012A1 (es) Forma de dosificacion de liberacion controlada que contiene lercadinipina y un acido que mejora el funcionamiento
CL2007000667A1 (es) Composicion farmaceutica que comprende al acido 7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]pirrol-1-il]-3,5-dihidroxi-heptanoico o una sal y al menos un agente estabilizante; procedimiento de preparacion, util en e
TR200604349A2 (tr) Aripiprazol içeren farmasötik bileşimler
BR112014004753A2 (pt) formulação de liberação de multicamadas
TR201803451T4 (tr) Olmesartan formülasyonlari.

Legal Events

Date Code Title Description
FB Suspension of granting procedure